CEL-SCI Corp (CVM) Closes $5M Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
CEL-SCI Announces Closing of $5 Million Offering
December 31, 2024 4:05 PM ESTVIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (CEL-SCI or the Company) (NYSE American: CVM), a cancer immunotherapy company, today announced the closing of its previously announced best-efforts offering of 16,130,000 shares of its common stock (or pre-funded warrants (Pre-Funded Warrants) in lieu thereof). Each share of common stock (or Pre-Funded Warrant) was sold at an offering price of $0.31 per share (inclusive of the Pre-Funded Warrant exercise price), for gross proceeds of approximately $5,000,000, before deducting placement agent fees and other offering expenses. All the shares and Pre-Funded Warrants in the offering were offered by the... More



